Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose Study
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
DS-7309 is being developed for the treatment of type 2 diabetes mellitus (T2DM). This will be
a randomized, placebo-controlled, blinded, sequential, multiple ascending dose study to
assess the safety, tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of multiple
doses of DS-7309 in subjects with T2DM.